ridaforolimus

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hematologic Malignancies

Conditions

Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes, Myeloid Metaplasia, Lymphoma

Trial Timeline

Jun 1, 2004 → Jun 1, 2006

NCT ID

NCT00086125

About ridaforolimus

ridaforolimus is a phase 2 stage product being developed by Merck for Hematologic Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT00086125. Target conditions include Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01431534	Phase 1	Terminated	Jan 30, 2012	May 25, 2018	Solid Tumors
NCT01380184	Phase 1	Completed	Jul 5, 2011	Apr 5, 2012	Cancer, Advanced
NCT01296659	Phase 1	Withdrawn	Feb 1, 2011	Aug 1, 2011	Soft Tissue Sarcoma
NCT01043887	Phase 1	Completed	Jan 1, 2010	Apr 1, 2010	Healthy Volunteers
NCT01010672	Phase 2	Completed	Nov 1, 2009	Jan 1, 2013	Sarcoma
NCT00694083	Phase 1	Completed	Jun 10, 2008	Sep 6, 2009	Neoplasm
NCT00704054	Phase 1	Completed	Jan 1, 2008	Jun 1, 2010	Solid Tumors
NCT00122343	Phase 2	Completed	Aug 1, 2005	Jan 1, 2008	Endometrial Cancer
NCT00110188	Phase 2	Completed	May 1, 2005	Aug 1, 2007	Prostate Cancer
NCT00112372	Phase 1	Completed	May 1, 2005	Mar 1, 2009	Cancer
NCT00093080	Phase 2	Completed	Oct 1, 2004	Nov 1, 2008	Leiomyosarcoma
NCT00086125	Phase 2	Completed	Jun 1, 2004	Jun 1, 2006	Hematologic Malignancies
NCT00060645	Phase 1	Completed	May 1, 2003	Feb 1, 2009	Tumors
NCT00060632	Phase 1	Completed	Apr 1, 2003	Oct 1, 2005	Tumors

Competing Products

20 competing products in Hematologic Malignancies

See all competitors

Product	Company	Stage	Hype Score
120 mg LY2784544	Eli Lilly	Phase 2	52
RLYB116 for Injection	Rallybio	Phase 1	25
DS3790a + Combination drug + Combination drug	Daiichi Sankyo	Phase 1/2	41
Isavuconazole	Astellas Pharma	Phase 2	52
isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral	Astellas Pharma	Phase 1	33
DSP-5336 + [14C]-DSP-5336	Sumitomo Pharma	Phase 1	33
BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib	Sumitomo Pharma	Phase 1	33
Venetoclax + ethinyl estradiol/levonorgestrel	AbbVie	Phase 1	33
ABT-888 + Temozolomide	AbbVie	Phase 1	33
ABBV-101	AbbVie	Phase 1	33
elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection	AbbVie	Phase 2	52
Capivasertib + Rabeprazole	AstraZeneca	Phase 1	33
AZD9829 + AZD9829	AstraZeneca	Phase 1/2	41
Pembrolizumab/vibostolimab coformulation	Merck	Phase 2	52
Nemtabrutinib	Merck	Phase 1	33
Ondansetron + Aprepitant	Merck	Phase 2	52
Nemtabrutinib	Merck	Phase 2	52
ARQ 621	Merck	Phase 1	33
Nemtabrutinib	Merck	Phase 1	33
Pelabresib	Novartis	Phase 3	77

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved